Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
NYU Langone Arena Oncology Dept.ofArenaOncologyAssoc(2)
mi
from
Lake Success, NY
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
NYU Langone Arena Oncology Dept.ofArenaOncologyAssoc(2)
mi
from
Lake Success, NY
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
Duke University Medical Center Dept. of DUMC (2)
mi
from
Durham, NC
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
Duke University Medical Center Dept. of DUMC (2)
mi
from
Durham, NC
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
Northwest Cancer Specialists Tutlatin
mi
from
Portland, OR
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
Northwest Cancer Specialists Tutlatin
mi
from
Portland, OR
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
University of Pittsburgh Cancer Institute DeptofMageeWomen'sHospital(2)
mi
from
Pittsburgh, PA
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
University of Pittsburgh Cancer Institute DeptofMageeWomen'sHospital(2)
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
The Jones Clinic Dept .of The Jones Clinic (3)
mi
from
Germantown, TN
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
The Jones Clinic Dept .of The Jones Clinic (3)
mi
from
Germantown, TN
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
Sarah Cannon Research Institute Dept.ofSarahCannonCancerCtr(6)
mi
from
Nashville, TN
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
Sarah Cannon Research Institute Dept.ofSarahCannonCancerCtr(6)
mi
from
Nashville, TN
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
Texas Cancer Center ( Medical City Dallas Hospital) Dept. of Texas Cancer Ctr. (2)
mi
from
Dallas, TX
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
Texas Cancer Center ( Medical City Dallas Hospital) Dept. of Texas Cancer Ctr. (2)
mi
from
Dallas, TX
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
Texas Oncology, P.A. Presbyterian Hospital (2)
mi
from
Dallas, TX
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
Texas Oncology, P.A. Presbyterian Hospital (2)
mi
from
Dallas, TX
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
Texas Oncology, P.A. Texas Onc - Amarillo
mi
from
Dallas, TX
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
Texas Oncology, P.A. Texas Onc - Amarillo
mi
from
Dallas, TX
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
Texas Oncology, P.A. Texas Oncology - Sammons
mi
from
Dallas, TX
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
Texas Oncology, P.A. Texas Oncology - Sammons
mi
from
Dallas, TX
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
Texas Oncology, P.A. Midtown
mi
from
Dallas, TX
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
Texas Oncology, P.A. Midtown
mi
from
Dallas, TX
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
University of Texas Southwestern Medical Center University of TX SW Med Ctr(2)
mi
from
Dallas, TX
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
University of Texas Southwestern Medical Center University of TX SW Med Ctr(2)
mi
from
Dallas, TX
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
University of Texas/MD Anderson Cancer Center Dept of MD Anderson (17)
mi
from
Houston, TX
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
University of Texas/MD Anderson Cancer Center Dept of MD Anderson (17)
mi
from
Houston, TX
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
Baylor College of Medicine Baylor
mi
from
Houston, TX
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
Baylor College of Medicine Baylor
mi
from
Houston, TX
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
Longview Cancer Center Longview Cancer Center (2)
mi
from
Longview, TX
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
Longview Cancer Center Longview Cancer Center (2)
mi
from
Longview, TX
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
Cancer Care Centers of South Texas / HOAST CCC of So. TX- San Antonio(2)
mi
from
San Antonio, TX
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
Cancer Care Centers of South Texas / HOAST CCC of So. TX- San Antonio(2)
mi
from
San Antonio, TX
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
South Texas Oncology and Hematology, PA South Texas Oncology (2)
mi
from
San Antonio, TX
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
South Texas Oncology and Hematology, PA South Texas Oncology (2)
mi
from
San Antonio, TX
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
Tyler Cancer Center Dept.ofTylerCancerCtr. (2)
mi
from
Tyler, TX
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
Tyler Cancer Center Dept.ofTylerCancerCtr. (2)
mi
from
Tyler, TX
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
Utah Cancer Specialists Utah Cancer (2)
mi
from
Salt Lake City, UT
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
Utah Cancer Specialists Utah Cancer (2)
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
Virginia Cancer Specialists, PC Dept.ofFairfaxNo.VA (2)
mi
from
Fairfax, VA
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
Virginia Cancer Specialists, PC Dept.ofFairfaxNo.VA (2)
mi
from
Fairfax, VA
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
Virginia Oncology Associates Dept. of VOA (2)
mi
from
Norfolk, VA
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
Virginia Oncology Associates Dept. of VOA (2)
mi
from
Norfolk, VA
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
Swedish Cancer Institute Swedish Cancer Institute
mi
from
Seattle, WA
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
Swedish Cancer Institute Swedish Cancer Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
St. Vincent Hospital/Green Bay Oncology
mi
from
Green Bay, WI
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
St. Vincent Hospital/Green Bay Oncology
mi
from
Green Bay, WI
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
Novartis Investigative Site
mi
from
C A B A,
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
Novartis Investigative Site
mi
from
C A B A,
Click here to add this to my saved trials
Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
Control of Vasomotor Symptoms in Women Treated for Breast Cancer
Status: Enrolling
Updated:  10/13/2015
MBCCOP - Gulf Coast
mi
from
Mobile, AL
Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
Control of Vasomotor Symptoms in Women Treated for Breast Cancer
Status: Enrolling
Updated: 10/13/2015
MBCCOP - Gulf Coast
mi
from
Mobile, AL
Click here to add this to my saved trials
Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
Control of Vasomotor Symptoms in Women Treated for Breast Cancer
Status: Enrolling
Updated:  10/13/2015
CCOP - Greater Phoenix
mi
from
Phoenix, AZ
Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
Control of Vasomotor Symptoms in Women Treated for Breast Cancer
Status: Enrolling
Updated: 10/13/2015
CCOP - Greater Phoenix
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
Control of Vasomotor Symptoms in Women Treated for Breast Cancer
Status: Enrolling
Updated:  10/13/2015
CCOP - Scottsdale Oncology Program
mi
from
Scottsdale, AZ
Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
Control of Vasomotor Symptoms in Women Treated for Breast Cancer
Status: Enrolling
Updated: 10/13/2015
CCOP - Scottsdale Oncology Program
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
Control of Vasomotor Symptoms in Women Treated for Breast Cancer
Status: Enrolling
Updated:  10/13/2015
CCOP - Colorado Cancer Research Program, Incorporated
mi
from
Denver, CO
Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
Control of Vasomotor Symptoms in Women Treated for Breast Cancer
Status: Enrolling
Updated: 10/13/2015
CCOP - Colorado Cancer Research Program, Incorporated
mi
from
Denver, CO
Click here to add this to my saved trials
Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
Control of Vasomotor Symptoms in Women Treated for Breast Cancer
Status: Enrolling
Updated:  10/13/2015
MBCCOP - Hawaii
mi
from
Honolulu, HI
Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
Control of Vasomotor Symptoms in Women Treated for Breast Cancer
Status: Enrolling
Updated: 10/13/2015
MBCCOP - Hawaii
mi
from
Honolulu, HI
Click here to add this to my saved trials
Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
Control of Vasomotor Symptoms in Women Treated for Breast Cancer
Status: Enrolling
Updated:  10/13/2015
CCOP - Central Illinois
mi
from
Decatur, IL
Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
Control of Vasomotor Symptoms in Women Treated for Breast Cancer
Status: Enrolling
Updated: 10/13/2015
CCOP - Central Illinois
mi
from
Decatur, IL
Click here to add this to my saved trials
Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
Control of Vasomotor Symptoms in Women Treated for Breast Cancer
Status: Enrolling
Updated:  10/13/2015
CCOP - Wichita
mi
from
Wichita, KA
Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
Control of Vasomotor Symptoms in Women Treated for Breast Cancer
Status: Enrolling
Updated: 10/13/2015
CCOP - Wichita
mi
from
Wichita, KA
Click here to add this to my saved trials
Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
Control of Vasomotor Symptoms in Women Treated for Breast Cancer
Status: Enrolling
Updated:  10/13/2015
CCOP - Kalamazoo
mi
from
Kalamazoo, MI
Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
Control of Vasomotor Symptoms in Women Treated for Breast Cancer
Status: Enrolling
Updated: 10/13/2015
CCOP - Kalamazoo
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
Control of Vasomotor Symptoms in Women Treated for Breast Cancer
Status: Enrolling
Updated:  10/13/2015
CCOP - Metro-Minnesota
mi
from
Saint Louis Park, MN
Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
Control of Vasomotor Symptoms in Women Treated for Breast Cancer
Status: Enrolling
Updated: 10/13/2015
CCOP - Metro-Minnesota
mi
from
Saint Louis Park, MN
Click here to add this to my saved trials
Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
Control of Vasomotor Symptoms in Women Treated for Breast Cancer
Status: Enrolling
Updated:  10/13/2015
CCOP - Northern New Jersey
mi
from
Hackensack, NJ
Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
Control of Vasomotor Symptoms in Women Treated for Breast Cancer
Status: Enrolling
Updated: 10/13/2015
CCOP - Northern New Jersey
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
Control of Vasomotor Symptoms in Women Treated for Breast Cancer
Status: Enrolling
Updated:  10/13/2015
CCOP - North Shore University Hospital
mi
from
Manhasset, NY
Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
Control of Vasomotor Symptoms in Women Treated for Breast Cancer
Status: Enrolling
Updated: 10/13/2015
CCOP - North Shore University Hospital
mi
from
Manhasset, NY
Click here to add this to my saved trials
Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
Control of Vasomotor Symptoms in Women Treated for Breast Cancer
Status: Enrolling
Updated:  10/13/2015
CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C.
mi
from
Syracuse, NY
Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
Control of Vasomotor Symptoms in Women Treated for Breast Cancer
Status: Enrolling
Updated: 10/13/2015
CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C.
mi
from
Syracuse, NY
Click here to add this to my saved trials
Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
Control of Vasomotor Symptoms in Women Treated for Breast Cancer
Status: Enrolling
Updated:  10/13/2015
CCOP - Southeast Cancer Control Consortium
mi
from
Winston-Salem, NC
Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
Control of Vasomotor Symptoms in Women Treated for Breast Cancer
Status: Enrolling
Updated: 10/13/2015
CCOP - Southeast Cancer Control Consortium
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
Control of Vasomotor Symptoms in Women Treated for Breast Cancer
Status: Enrolling
Updated:  10/13/2015
CCOP - Columbus
mi
from
Columbus, OH
Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
Control of Vasomotor Symptoms in Women Treated for Breast Cancer
Status: Enrolling
Updated: 10/13/2015
CCOP - Columbus
mi
from
Columbus, OH
Click here to add this to my saved trials
Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
Control of Vasomotor Symptoms in Women Treated for Breast Cancer
Status: Enrolling
Updated:  10/13/2015
CCOP - Dayton
mi
from
Dayton, OH
Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
Control of Vasomotor Symptoms in Women Treated for Breast Cancer
Status: Enrolling
Updated: 10/13/2015
CCOP - Dayton
mi
from
Dayton, OH
Click here to add this to my saved trials
Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
Control of Vasomotor Symptoms in Women Treated for Breast Cancer
Status: Enrolling
Updated:  10/13/2015
CCOP - Virginia Mason Research Center
mi
from
Seattle, WA
Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
Control of Vasomotor Symptoms in Women Treated for Breast Cancer
Status: Enrolling
Updated: 10/13/2015
CCOP - Virginia Mason Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
Control of Vasomotor Symptoms in Women Treated for Breast Cancer
Status: Enrolling
Updated:  10/13/2015
CCOP - Northwest
mi
from
Tacoma, WA
Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
Control of Vasomotor Symptoms in Women Treated for Breast Cancer
Status: Enrolling
Updated: 10/13/2015
CCOP - Northwest
mi
from
Tacoma, WA
Click here to add this to my saved trials
Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
Control of Vasomotor Symptoms in Women Treated for Breast Cancer
Status: Enrolling
Updated:  10/13/2015
CCOP - Marshfield Medical Research and Education Foundation
mi
from
Marshfield, WI
Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
Control of Vasomotor Symptoms in Women Treated for Breast Cancer
Status: Enrolling
Updated: 10/13/2015
CCOP - Marshfield Medical Research and Education Foundation
mi
from
Marshfield, WI
Click here to add this to my saved trials
Aerobic Exercise, Resistance Exercise, or Flexibility and Relaxation Training in Inactive Older Female Breast Cancer Survivors
Comparison of Aerobic and Resistance Exercise in Older Breast Cancer Survivors
Status: Enrolling
Updated:  10/13/2015
Knight Cancer Institute at Oregon Health and Science University
mi
from
Portland, OR
Aerobic Exercise, Resistance Exercise, or Flexibility and Relaxation Training in Inactive Older Female Breast Cancer Survivors
Comparison of Aerobic and Resistance Exercise in Older Breast Cancer Survivors
Status: Enrolling
Updated: 10/13/2015
Knight Cancer Institute at Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Scripps Polster Breast Care Center Investigational GeneBank
Scripps Polster Breast Care Center Investigational GeneBank
Status: Enrolling
Updated:  10/14/2015
Scripps Polster Breast Care Center
mi
from
La Jolla, CA
Scripps Polster Breast Care Center Investigational GeneBank
Scripps Polster Breast Care Center Investigational GeneBank
Status: Enrolling
Updated: 10/14/2015
Scripps Polster Breast Care Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Irinotecan and Etoposide in Treating Patients With Recurrent, Locally Advanced, or Metastatic Breast Cancer
A Phase II Study: Irinotecan and Etoposide as Treatment for Refractory, Metastatic Breast Cancer
Status: Enrolling
Updated:  10/15/2015
Arizona Cancer Center at University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Irinotecan and Etoposide in Treating Patients With Recurrent, Locally Advanced, or Metastatic Breast Cancer
A Phase II Study: Irinotecan and Etoposide as Treatment for Refractory, Metastatic Breast Cancer
Status: Enrolling
Updated: 10/15/2015
Arizona Cancer Center at University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
S0927: Omega-3-Fatty Acid Supplements in Treating Muscle and Bone Pain and Stiffness in Pts W/Stage I, II, or III Breast Cancer Receiving Hormone Therapy
S0927: A Randomized Placebo-Controlled Trial of Omega-3-Fatty Acid for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain and Stiffness In Women With Early Stage Breast Cancer, Phase III
Status: Enrolling
Updated:  10/15/2015
Providence Cancer Center at Providence Hospital
mi
from
Mobile, AL
S0927: Omega-3-Fatty Acid Supplements in Treating Muscle and Bone Pain and Stiffness in Pts W/Stage I, II, or III Breast Cancer Receiving Hormone Therapy
S0927: A Randomized Placebo-Controlled Trial of Omega-3-Fatty Acid for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain and Stiffness In Women With Early Stage Breast Cancer, Phase III
Status: Enrolling
Updated: 10/15/2015
Providence Cancer Center at Providence Hospital
mi
from
Mobile, AL
Click here to add this to my saved trials
S0927: Omega-3-Fatty Acid Supplements in Treating Muscle and Bone Pain and Stiffness in Pts W/Stage I, II, or III Breast Cancer Receiving Hormone Therapy
S0927: A Randomized Placebo-Controlled Trial of Omega-3-Fatty Acid for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain and Stiffness In Women With Early Stage Breast Cancer, Phase III
Status: Enrolling
Updated:  10/15/2015
Alaska Regional Hospital Cancer Center
mi
from
Anchorage, AK
S0927: Omega-3-Fatty Acid Supplements in Treating Muscle and Bone Pain and Stiffness in Pts W/Stage I, II, or III Breast Cancer Receiving Hormone Therapy
S0927: A Randomized Placebo-Controlled Trial of Omega-3-Fatty Acid for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain and Stiffness In Women With Early Stage Breast Cancer, Phase III
Status: Enrolling
Updated: 10/15/2015
Alaska Regional Hospital Cancer Center
mi
from
Anchorage, AK
Click here to add this to my saved trials
S0927: Omega-3-Fatty Acid Supplements in Treating Muscle and Bone Pain and Stiffness in Pts W/Stage I, II, or III Breast Cancer Receiving Hormone Therapy
S0927: A Randomized Placebo-Controlled Trial of Omega-3-Fatty Acid for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain and Stiffness In Women With Early Stage Breast Cancer, Phase III
Status: Enrolling
Updated:  10/15/2015
Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital
mi
from
Fairbanks, AK
S0927: Omega-3-Fatty Acid Supplements in Treating Muscle and Bone Pain and Stiffness in Pts W/Stage I, II, or III Breast Cancer Receiving Hormone Therapy
S0927: A Randomized Placebo-Controlled Trial of Omega-3-Fatty Acid for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain and Stiffness In Women With Early Stage Breast Cancer, Phase III
Status: Enrolling
Updated: 10/15/2015
Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital
mi
from
Fairbanks, AK
Click here to add this to my saved trials
S0927: Omega-3-Fatty Acid Supplements in Treating Muscle and Bone Pain and Stiffness in Pts W/Stage I, II, or III Breast Cancer Receiving Hormone Therapy
S0927: A Randomized Placebo-Controlled Trial of Omega-3-Fatty Acid for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain and Stiffness In Women With Early Stage Breast Cancer, Phase III
Status: Enrolling
Updated:  10/15/2015
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
S0927: Omega-3-Fatty Acid Supplements in Treating Muscle and Bone Pain and Stiffness in Pts W/Stage I, II, or III Breast Cancer Receiving Hormone Therapy
S0927: A Randomized Placebo-Controlled Trial of Omega-3-Fatty Acid for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain and Stiffness In Women With Early Stage Breast Cancer, Phase III
Status: Enrolling
Updated: 10/15/2015
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
S0927: Omega-3-Fatty Acid Supplements in Treating Muscle and Bone Pain and Stiffness in Pts W/Stage I, II, or III Breast Cancer Receiving Hormone Therapy
S0927: A Randomized Placebo-Controlled Trial of Omega-3-Fatty Acid for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain and Stiffness In Women With Early Stage Breast Cancer, Phase III
Status: Enrolling
Updated:  10/15/2015
Kaiser Permanente Medical Center - Anaheim/Orange County
mi
from
Anaheim, CA
S0927: Omega-3-Fatty Acid Supplements in Treating Muscle and Bone Pain and Stiffness in Pts W/Stage I, II, or III Breast Cancer Receiving Hormone Therapy
S0927: A Randomized Placebo-Controlled Trial of Omega-3-Fatty Acid for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain and Stiffness In Women With Early Stage Breast Cancer, Phase III
Status: Enrolling
Updated: 10/15/2015
Kaiser Permanente Medical Center - Anaheim/Orange County
mi
from
Anaheim, CA
Click here to add this to my saved trials